DOCSLIB.ORG

Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors REVIEW

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors REVIEW REVIEW DOI: 10.4274/tjh.galenos.2018.2018.0150 Turk J Hematol 2019;36:1-11 Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors Çocukluk Çağı Akut Lenfoblastik Lösemi Tedavisi Sonrası Geç Yan Etkiler Hande Kızılocak1, Fatih Okcu2 1Istanbul University-Cerrahpaşa Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey 2Texas Children’s Hematology and Oncology Centers, Baylor College of Medicine, Department of Pediatrics, Division of Hematology and Oncology, Houston, TX, USA Abstract Öz Over the last 50 years, the survival rates in children with acute Son 50 yıldaki gelişmeler ile akut lenfoblastik lösemili (ALL) lymphoblastic leukemia (ALL) have increased remarkably. The optimal çocuklardaki tedavi sonrası sağkalım oranında belirgin derecede artış use of antileukemic agents in cooperative group protocols, central saptandı. Antilösemik ilaçların akılcı kullanımı, santral sinir sistemini nervous system-directed treatment, improvements in supportive hedefleyen lokal tedaviler ve destek tedavisindeki gelişmeler ile 5 care, and recognition of biological, clinical, and treatment response yıllık olaysız sağkalım %85’e ve 5 yıllık genel sağkalım %90’a ulaştı. characteristics that predict patients with a higher or a lower risk of Uzamış sağkalım süreleri, tedavinin uzun dönem yan etkilerine olan treatment failure have improved 5-year event-free survival rates, farkındalığı da arttırdı. Geç dönem mortalite, ikincil maligniteler, reaching more than 85%, and 5-year overall survival rates, reaching nörolojik, kardiyak, endokrin ve psikososyal bozukluklar ALL tedavisi more than 90%. Consequently, it has become increasingly important to sonrası sık görülen yan etkilerdir. Son yıllarda Avrupa ve Amerika characterize the occurrence of long-term late effects. ALL treatments Birleşik Devletleri’ndeki birçok grup ALL tedavisi sonrası uzun dönem have been associated with increased risks for adverse outcomes such yan etkiler konusunda çalışmalar yaptı, takip için ve uzun dönem as late mortality, secondary malignancies, and neurological, cardiac, mortalite ve morbiditeyi azaltmak için yeni yaklaşımlar önerdiler. endocrine, and social/psychological disorders. In recent decades, Günümüzde kullanımda olan protokoller uzun dönem yan etkileri cooperative groups in Europe and in the United States have provided önlemek için tedavinin yoğunluğunu azaltmaya çalışırken, sağkalımla essential information about the long-term effects of ALL therapy, iligili çalışmalarda da yan etkilerin öngörülmesi ve gerekli önlem ve giving recommendations for screening as well as facilitating new tedavilerin sağlanması konusu irdeleniyor. approaches for reducing late-term morbidity and mortality. Current Anahtar Sözcükler: Akut lenfoblastik lösemi, Kanser tedavisi sonrası frontline protocols continue to examine ways to lower the intensity sağkalım, Geç yan etkiler and amount of therapy to reduce late effects, whereas survivorship studies attempt to predict such adverse effects precisely and develop targeted prevention and treatment strategies. Keywords: Acute lymphoblastic leukemia, Cancer survivorship, Late effects Introduction late effects related to therapy (summarized in Table 1). In recent decades, cooperative groups in Europe and in the United States In the last 50 years remarkable success in treating childhood have prioritized development of treatment regimens aimed at acute lymphoblastic leukemia (ALL) has been achieved through reducing the risk for late effects without adversely impacting modifications of chemotherapy and radiotherapy within the cure rates. While traditional and molecular epidemiology cooperative group trials and improved supportive care [1]. As studies are pursued to describe the growing spectrum of late a result, it has become obvious that survivors of childhood ALL effects seen in such survivors, development of interventions have, in the long term, increased risks of life-threatening severe to prevent and treat late effects associated with significant ©Copyright 2019 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House Address for Correspondence/Yazışma Adresi: Hande KIZILOCAK, M.D., Received/Geliş tarihi: May 02, 2018 Istanbul University-Cerrahpaşa Faculty of Medicine, Department of Pediatric Hematology and Oncology, İstanbul, Turkey Accepted/Kabul tarihi: July 04, 2018 Phone : +90 323-361-5798 E-mail : [email protected] ORCID-ID: orcid.org/0000-0003-0323-2571 1 Kızılocak H and Okcu F: Late Effects in Childhood Acute Lymphoblastic Leukemia Turk J Hematol 2019;36:1-11 mortality and morbidity has emerged as an important field of 6-mercaptopurine and methotrexate. Such success inspired of research. In this manuscript we present a comprehensive the development of similar clinical trials around the world, review of the epidemiology and burden of common late effects including two particularly important studies in the 1970s [7,8]. observed among childhood ALL survivors including secondary First the Berlin-Frankfurt-Munster group presented its “Protocol malignancies and neurological, cardiac, endocrine, and social/ II” treatment, specifying a reinduction phase (i.e. the repetition psychological disorders. of the initial remission induction therapy, which is now referred to as delayed intensification). Secondly, the Dana-Farber Cancer Evolution of Acute Lymphoblastic Leukemia Therapy Center added weekly asparaginase at a high dose into its multiagent protocol. The optimal use of antileukemic agents in cooperative group protocols, central nervous system (CNS)-directed treatment, Simultaneously, in the 1970s, the use of prophylactic improvements in supportive care, and recognition of biological, craniospinal radiation was the next major step in the evolution clinical, and treatment response characteristics able to predict of treatment of ALL [9]. While only 2% of children with ALL have patients at higher or lower risks of treatment failures have overt leukemia in the spinal fluid at diagnosis, approximately increased 5-year event-free survival (EFS) rates to above 85% half will experience a CNS relapse if given systemic therapy and 5-year overall survival (OS) rates to above 90% [2], while alone. Craniospinal radiation led to several detrimental late few children survived 50 years ago [3]. effects including cognitive impairment, growth arrest, and panhypopituitarism in most of the patients [10,11]. To reduce After the initial single agent (aminopterin) and two-drug these adverse outcomes first spine radiation was eliminated, combinations (mercaptopurine and methotrexate) produced followed by reductions in the cranial radiation dose from breakthrough “temporary remissions” in the 1940s and 24 to 18 Gy and then eventually to 12 Gy. Thus, in 1980s, 1950s [4,5] Pinkel and colleagues developed a multiphase cranial radiotherapy (CRT) became a standard component of ALL treatment protocol in 1962 [6]. This included remission successful multimodality therapy for treating and preventing induction, CNS-directed therapy [including both cranial CNS leukemia [12]. However, many children were still left irradiation and intrathecal (IT) methotrexate], intensification with neurocognitive impairment that manifested as impaired (consolidation), and continuation treatment using a combination processing speed, global intellectual function, and executive Table 1. Summary of late effects in childhood acute lymphoblastic leukemia. Late effects Associated variables Frequency Screening methods References Radiation, cardiopulmonary Death from any Lifelong periodic ROS*/ Late mortality [15,16,17,18,19] diseases, SN, recurrences cause, 13% physical exam Radiation, chemotherapy Secondary Lifelong periodic ROS/ (alkylating agents, 1%-6% [20,21,22,23,24,25,26,27,28,29] Malignancy physical exam anthracyclines, and etoposide) Lifelong periodic ROS/ Neurological/ Cranial or craniospinal radiation, physical exam; neurological [30,31,32,33,34,35,36,37,38,39,40, Neurocognitive methotrexate (IT/IV), IT ARA-C, 20%-40% examination, imaging as 41,42,43,44,45,46,47,48,49,50] disorders vincristine, steroids needed Anthracycline Lifelong periodic ROS/ <500 mg/m2, physical exam focused on Anthracycline therapy, [52,53,54,55,56,57,58,59,60,61, Cardiotoxicity CHF 10%, cardiac system, periodic overweight 62,63,64] >600 mg/m2: echocardiography, blood CHF 36% pressure monitoring Endocrine disorders (growth hormone Clinical dietician evaluation, [66,67,68,69,70,71,72,73,74,75,76, Cranial radiation, younger age Obesity, deficiency, healthy diet, and regular 77,78,79,80,81,82,83,84,85,86, at diagnosis, female sex precocious puberty, 12%-28% physical exercise 87,88,89] obesity) High-dose methotrexate, Bone disorders mercaptopurine, glucocorticoids, Symptomatic Increased physical activity [90,91,92,93,94,95,96,97,98,99, (osteoporosis, cranial radiation, low calcium osteonecrosis, and calcium intake 100,101,102,103] osteonecrosis) intake, decreased physical 1%-38% activity, obesity Social/Psychological Young age at diagnosis, Consultancy and education Not measured well [15,23,104,105,106] disorders female sex to parents and survivors ROS: Review of systems, SN: secondary neoplasm, IT: intrathecal. 2 Turk J Hematol 2019;36:1-11 Kızılocak H and Okcu F: Late Effects in Childhood Acute Lymphoblastic Leukemia function. Ultimately a number of randomized studies showed years from the initial diagnosis, those ALL patients still surviving that IT chemoprophylaxis with methotrexate or “triple” therapy are seen
Load more

Recommended publications
  • Late Effects of Treatment
    Late Effects of Treatment A Guide for Patients Introduction Your cancer treatment can cause side effects. Some of these will occur at the time of treatment and will normally stop when treatment ends. Some of these side effects may last for a long time after treatment; these are long- term effects. Some side effects do not occur for months or even years after treatment ends; these side effects are called late effects. These late effects can be physical or emotional. Not everyone gets late effects, the risk depends on the type of treatment, the dose of treatment and the patient’s age at the time of treatment. This booklet is designed to and peer reviewed by Dr Panos provide you with information Kottaridis, Royal Free Hospital. about the late effects you may The rewrite was put together by experience, what to expect and Lisa Lovelidge and reviewed by how they may be managed. If Dr Victoria Grandage. We are also you need specific advice or are grateful to our patient reviewers, concerned about a particular Simon Walker, John Watson and late effect, please contact your Steve Colbourne and the Brighton medical team or Clinical Nurse support group. The booklet has Specialist. since been updated by our Patient Information Writer, Isabelle Leach. This booklet has been compiled by Dr Victoria Grandage (UCLH) If you would like any information on the sources used for this booklet, please email [email protected] for a list of references. Version 3 Printed: 10/2020 2 www.leukaemiacare.org.uk Review date: 10/2022 In this booklet Introduction
    [Show full text]
  • ICD-10-CM Official Guidelines for Coding and Reporting FY 2016
    ICD-10-CM Official Guidelines for Coding and Reporting FY 2016 Narrative changes appear in bold text Items underlined have been moved within the guidelines since the FY 2014 version Italics are used to indicate revisions to heading changes The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). These guidelines should be used as a companion document to the official version of the ICD-10- CM as published on the NCHS website. The ICD-10-CM is a morbidity classification published by the United States for classifying diagnoses and reason for visits in all health care settings. The ICD-10-CM is based on the ICD-10, the statistical classification of disease published by the World Health Organization (WHO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-10-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-10-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in the Tabular List and Alphabetic Index of ICD-10-CM, but provide additional instruction.
    [Show full text]
  • ICD-10-CM Official Guidelines for Coding and Reporting FY 2018 (October 1, 2017 - September 30, 2018)
    ICD-10-CM Official Guidelines for Coding and Reporting FY 2018 (October 1, 2017 - September 30, 2018) Narrative changes appear in bold text Items underlined have been moved within the guidelines since the FY 2017 version Italics are used to indicate revisions to heading changes The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). These guidelines should be used as a companion document to the official version of the ICD-10- CM as published on the NCHS website. The ICD-10-CM is a morbidity classification published by the United States for classifying diagnoses and reason for visits in all health care settings. The ICD-10-CM is based on the ICD-10, the statistical classification of disease published by the World Health Organization (WHO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-10-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-10-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in the Tabular List and Alphabetic Index of ICD-10-CM, but provide additional instruction.
    [Show full text]
  • Late Effects of Cancer Treatments Noreen M
    6 Late Effects of Cancer Treatments Noreen M. Aziz Background and Significance such as cigarette smoke or toxins such as alcohol are largely unknown.2,6,12 With continued advances in strategies to detect cancer early Thus, there is today a greater recognition of symptoms and treat it effectively, along with the aging of the population, that persist after the completion of treatment and which arise the number of individuals living years beyond a cancer diag- years after primary therapy. Both acute organ toxicities such nosis can be expected to continue to increase. Statistical as radiation pneumonitis and chronic toxicities such as con- trends show that, in the absence of other competing causes gestive cardiac failure, neurocognitive deficits, infertility, and of death, 64% of adults diagnosed with cancer today can second malignancies are being described as the price of cure 2,6,12 expect to be alive in 5 years.1–4 Relative 5-year survival rates or prolonged survival. The study of late effects, originally for those diagnosed as children (age less than 19 years) are within the realm of pediatric cancer, is now germane to even higher, with almost 79% of childhood cancer survivors cancer survivors at all ages because concerns may continue 2,6 estimated to be alive at 5 years and 75% at 10 years.5 to surface throughout the life cycle. These concerns under- Survival from cancer has seen dramatic improvements score the need to follow up and screen survivors of cancer for over the past three decades, mainly as a result of advances in toxicities such as those mentioned and also to develop and early detection, therapeutic strategies, and the widespread use provide effective interventions that carry the potential to of combined modality therapy (surgery, chemotherapy, and prevent or ameliorate adverse outcomes.
    [Show full text]
  • Laughter Is the Best Medicine
    SUMMER 2019 • ISSUE 83 • Late effects A helping hand for families of children and young people with cancer Laughter is the best medicine Lynda McMahon shares her son Benjamin’s story, from intensive cancer treatment as a child to his debut in a successful West End comedy play. Benjamin was diagnosed with acute lymphoblastic leukaemia (ALL) when he Benjamin and his family was four years old and he went through three years of intensive chemotherapy. For Benjamin, the challenges were multiplied as he contracted pneumonia in the midst of his treatment. He was on life support and put into a drug-induced coma in the intensive care unit at The John Radcliffe Hospital in Oxford. Thanks to the professionalism of his medical teams and, most importantly, his own sheer determination, he pulled through with no brain damage, which we were told he may have suffered due to the period he was starved of oxygen. He spent a month in hospital learning to walk again and gaining strength before restarting chemotherapy as he still had the leukaemia to fight. Unfortunately, Benjamin’s cancer returned after 18 months of remission. He needed a further two years of chemotherapy and had cranial radiotherapy too as the leukaemia had reappeared in the fluid around his brain. With over 70 lumbar punctures and many general anaesthetics, viral encephalitis, shingles and a host of other infections and complications, this was more than enough for one little body. Benjamin missed a lot of school and INSIDE What are Coping with The science had to contend with being dyslexic THIS late effects? emotional late effects behind late effects Pages 6-7 Page 8 Page 10 (...continued on page 2) ISSUE: 2 Contact Issue 83: Late effects audience laugh out loud was so Cover story continued..
    [Show full text]
  • ICD-10 Coding Help Sheet
    ICD-10 Coding Help Sheet Abnormal Breathing Signs Aftercare: Acute Respiratory Distress – R06.03 Amputation – Z47.81 Apnea – R06.81 Note: Use additional code to identify Dyspnea – R06.00 limb amputated Z89.+++ Cheyne-Stoke (Periodic) – R06.3 Note: If due to DM ulcer add code Hyperventilation – R06.4 for the history of DM ulcer Z86.31 Orthopnea – R06.01 Breast Reconstruction, Post-Mastectomy – Shortness of Breath – R06.02 Z42.1 Stridor – R06.2 Fracture – Code the fracture Tachypnea – R06.82 Joint Explanation (staged procedure, Wheezing – R06.2 including a subsequent joint Abnormality of Gait replacement) - Z47.3+ Ataxic (staggering) Gait – R26.0 Note: If removed and not replaced Paralytic (spastic) Gait – R26.1 code the acquired absence of a joint Difficulty Walking (chronic limp) – R26.2 Hip – Z89.62+ Unsteadiness on feet – R26.81 Knee – Z89.52+ Musculoskeletal/Other – R26.89 Shoulder – Z89.23+ Unspecified – R26.9 Joint Replacement - Z47.1 Abnormal Weight Loss – R63.4 Note: Use additional code to identify Abrasion – See Superficial Skin Injury the joint Z96.6++ Absence of: Neoplasm Removal – Z48.3 Arm, Above Elbow – Z89.22+ Note: Use additional code to Arm, Below Elbow) – Z89.21+ identify the neoplasm (continued Breast – Z90.1+ treatment) or history of neoplasm Foot – Z89.43 (eradicated/no further treatment) Hand – Z89.11 Ortho NEC – Z47.89 Joint Note: Used for other orthopedic Hip – Z89.62+ surgeries, e.g. spinal surgery Knee – Z89.53+ Ostomies – Z43.+ Shoulder – Z89.23 Post-procedural Wound Closure – Z48.1 Leg, Above Knee – Z89.61+ Specified Body System Leg, Below Knee – Z89.51+ Sensory – Z48.810 Toe, Great – Z89.41 Neurological - Z48.811 Toe(s), Other – Z89.42 Circulatory - Z48.812 Abscess Respiratory - Z48.813 Abdominal Wall – L02.211 Digestive - Z48.815 Buttocks – L02.31 Genitourinary - Z48.816 Face – L02.01 Integumentary - Z48.817 Foot – L02.61+ Transplant – Z48.2+ Hand – L02.51+ Note: Aftercare is not coded if due to Limb – L02.41+ trauma, injury or if a complication is present.
    [Show full text]
  • ICD-9-CM Official Guidelines for Coding and Reporting
    ICD-9-CM Official Guidelines for Coding and Reporting Effective October 1, 2011 Narrative changes appear in bold text Items underlined have been moved within the guidelines since October 1, 2010 The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). These guidelines should be used as a companion document to the official version of the ICD-9- CM as published on CD-ROM by the U.S. Government Printing Office (GPO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-9-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are included on the official government version of the ICD-9-CM, and also appear in “Coding Clinic for ICD-9-CM” published by the AHA. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-9-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in Volumes I, II and III of ICD-9-CM, but provide additional instruction. Adherence to these guidelines when assigning ICD-9-CM diagnosis and procedure codes is required under the Health Insurance Portability and Accountability Act (HIPAA).
    [Show full text]
  • (001-139) Includes: Diseases Generally Recogniz
    ICD9 Cause of Death list 1 of 609 CLASSIFICATION OF DISEASES AND INJURIES I. INFECTIOUS AND PARASITIC DISEASES (001-139) Includes: diseases generally recognized as communicable or transmissible as well as a few diseases of unknown but possibly infectious origin Excludes: acute respiratory infections (460-466) influenza (487.-) certain localized infections Note: Categories for "late effects" of infectious and parasitic diseases are to be found at 137.- to 139.- INTESTINAL INFECTIOUS DISEASES (001-009) Excludes: helminthiases (120-129) 001 Cholera 001.0 Due to Vibrio cholerae 001.1 Due to Vibrio cholerae el tor 001.9 Unspecified 002 Typhoid and paratyphoid fevers 002.0 Typhoid fever Typhoid (fever) (infection) [any site] 002.1 Paratyphoid fever A 002.2 Paratyphoid fever B 002.3 Paratyphoid fever C 002.9 Paratyphoid fever, unspecified 003 Other salmonella infections Includes: infection or food poisoning by Salmonella [any serotype] ICD9 Cause of Death list 2 of 609 003.0 Salmonella gastroenteritis Salmonellosis 003.1 Salmonella septicaemia 003.2 Localized salmonella infections Salmonella: Salmonella: arthritis osteomyelitis meningitis pneumonia 003.8 Other 003.9 Unspecified Salmonella infection NOS 004 Shigellosis Includes: bacillary dysentery 004.0 Shigella dysenteriae Infection by group A Shigella (Schmitz) (Shiga) 004.1 Shigella flexneri Infection by group B Shigella 004.2 Shigella boydii Infection by group C Shigella 004.3 Shigella sonnei Infection by group D Shigella 004.8 Other 004.9 Unspecified 005 Other food poisoning (bacterial) Excludes: salmonella infections (003.-) toxic effect of noxious foodstuffs (988.-) ICD9 Cause of Death list 3 of 609 005.0 Staphylococcal food poisoning Staphylococcal toxaemia specified as due to food 005.1 Botulism Food poisoning due to Clostridium botulinum 005.2 Food poisoning due to Clostridium perfringens [Cl.
    [Show full text]
  • Chronic Myeloid Leukemia
    Chronic Myeloid Leukemia Paula, CML survivor This publication was supported by Revised 2014 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to finding cures for blood cancer patients. Our research grants have funded many of today’s most promising advances; we are the leading source of free blood cancer information, education and support; and we advocate for blood cancer patients and their families, helping to ensure they have access to quality, affordable and coordinated care. Since 1954, we have been a driving force behind almost every treatment breakthrough for blood cancer patients. We have invested more than $1 billion in research to advance therapies and save lives. Thanks to research and access to better treatments, survival rates for many blood cancer patients have doubled, tripled and even quadrupled. Yet we are far from done. Until there is a cure for cancer, we will continue to work hard—to fund new research, to create new patient programs and services, and to share information and resources about blood cancers. This booklet has information that can help you understand chronic myeloid leukemia (CML), prepare your questions, find answers and resources, and communicate better with members of your healthcare team. Our vision is that, one day, all people with CML will either be cured or will be able to manage their disease so that they can experience a great quality of life. Today, we hope our expertise, knowledge and resources will make a difference in your journey.
    [Show full text]
  • Late Effects of Childhood Cancer and Its Treatment
    Late Effects of Childhood Cancer and Its Treatment Wendy Landier, PhD, RN, Saro Armenian, DO, MPH, Smita Bhatia, MD, MPH* KEYWORDS Childhood Cancer Late effects Treatment KEY POINTS As survival rates for pediatric cancers continue to improve, the number of childhood cancer survivors continues to increase. The burden of long-term therapy-related morbidity experienced by childhood cancer survivors is substantial. Childhood cancer survivors require lifelong follow-up care to monitor for late treatment- related sequelae. INTRODUCTION With advances in therapeutic strategies for common childhood malignancies such as leukemia, lymphoma, and central nervous system (CNS) tumors, the number of child- hood cancer survivors in the United States continues to increase, and is estimated to exceed 500,000 by 2020.1 About 1 of every 530 young adults between 20 and 39 years of age in the United States is a childhood cancer survivor.2 Treatment of childhood cancer with chemotherapy, radiation, or hematopoietic cell transplant (HCT) can result in adverse sequelae, which may not become evident for many years. In this article, commonly occurring late effects associated with childhood cancer treatment are reviewed. BURDEN OF MORBIDITY The burden of morbidity experienced by childhood cancer survivors is substantial, as shown by the fact that approximately 40% of childhood cancer survivors experience a late effect that is severe, life threatening, disabling, or fatal at 30 years from diagnosis.3 A primary diagnosis of Hodgkin lymphoma (HL) or brain tumors and exposure to chest radiation or anthracyclines increases the risk of these chronic health conditions. Furthermore, the burden of morbidity increases as the cohort ages.4 HCT recipients experience a higher burden of morbidity when compared with childhood cancer Department of Population Sciences, City of Hope, 1500 E.
    [Show full text]
  • COG Long-Term Follow-Up Guidelines Guidelines Children’S Oncology Group
    Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 5.0 - October 2018 Website: www.survivorshipguidelines.org Copyright 2018 © Children’s Oncology Group All rights reserved worldwide Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 5.0 – October 2018 www.survivorshipguidelines.org Copyright 2018 © Children’s Oncology Group All rights reserved worldwide Generously supported by With special appreciation to Jocelyn M. York, BA, Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham, AL for editing and typesetting Contents Introductory Materials Page Section # Page Sex Therapeutic Agent Potential Late Effect Abstract x 14 18 Female Alkylating Agents Reduced ovarian follicular pool Disclaimer and Notice of Proprietary Rights xi 15 20 Alkylating Agents Acute myeloid leukemia; Myelodysplasia Contributors - Panel of Experts xii 16 21 Alkylating Agents Pulmonary fi brosis Contributors - Task Force Membership 2013-2018 xiii 17 22 Alkylating Agents Cataracts Contributors - Guideline Development Task Force - Initial Versions xviii 18 23 Alkylating Agents Urinary tract toxicity Contributors - Health Link Authors xviii 19 24 Alkylating Agents Bladder malignancy Preface xix 20 25 Alkylating Agents Renal toxicity Instructions for Use xxiii 21 26 Heavy Metals Ototoxicity New to Version 5.0 xxvi 22 28 Heavy Metals Peripheral sensory neuropathy 23 29 Heavy Metals Renal toxicity Section # Page Sex Therapeutic Agent
    [Show full text]
  • Icd-10-Cm Fy 2021-Covid
    ICD-10-CM Official Guidelines for Coding and Reporting FY 2021 – UPDATED January 1, 2021 (October 1, 2020 - September 30, 2021) Narrative changes appear in bold text Items underlined have been moved within the guidelines since the FY 2020 version Italics are used to indicate revisions to heading changes The National Center for Health Statistics (NCHS) and the Centers for Medicare and Medicaid Services (CMS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS) provide the following guidelines for coding and reporting using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). These guidelines should be used as a companion document to the official version of the ICD-10- CM as published on the NCHS website. The ICD-10-CM is a morbidity classification published by the United States for classifying diagnoses and reason for visits in all health care settings. The ICD-10-CM is based on the ICD-10, the statistical classification of disease published by the World Health Organization (WHO). These guidelines have been approved by the four organizations that make up the Cooperating Parties for the ICD-10-CM: the American Hospital Association (AHA), the American Health Information Management Association (AHIMA), CMS, and NCHS. These guidelines are a set of rules that have been developed to accompany and complement the official conventions and instructions provided within the ICD-10-CM itself. The instructions and conventions of the classification take precedence over guidelines. These guidelines are based on the coding and sequencing instructions in the Tabular List and Alphabetic Index of ICD-10-CM, but provide additional instruction.
    [Show full text]